

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM609478

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF SECURITY INTEREST IN SPECIFIED INTELLECTUAL PROPERTY		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
JPMORGAN CHASE BANK, N.A, as Collateral Agent		11/17/2020	Bank: UNITED STATES
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Syneos Health US, Inc.		
<b>Street Address:</b>	Independence Wharf, 470 Atlantic Avenue, 11th Floor		
<b>City:</b>	Boston		
<b>State/Country:</b>	MASSACHUSETTS		
<b>Postal Code:</b>	10010		
<b>Entity Type:</b>	Corporation: DELAWARE		
<b>PROPERTY NUMBERS Total: 5</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	5147092	PATIENT INHOME	
<b>Registration Number:</b>	5147089	PATIENT INOFFICE	
<b>Registration Number:</b>	5147091	PATIENT INPHARMACY	
<b>Registration Number:</b>	5147088	PHARMACIST INSTORE	
<b>Registration Number:</b>	5147090	PRESCRIBER INOFFICE	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	2023704750		
<b>Email:</b>	ipteam@cogencyglobal.com		
<b>Correspondent Name:</b>	Jennifer Tindie		
<b>Address Line 1:</b>	1025 Vermont Ave NW, Suite 1130		
<b>Address Line 2:</b>	COGENCY GLOBAL INC.		
<b>Address Line 4:</b>	Washington, D.C. 20005		
<b>ATTORNEY DOCKET NUMBER:</b>	1290961 TM SYNEOS		
<b>NAME OF SUBMITTER:</b>	Christian Craft		
<b>SIGNATURE:</b>	/Christian Craft/		

OP \$140.00 5147092

<b>DATE SIGNED:</b>	11/18/2020
---------------------	------------

**Total Attachments: 5**

source=Syneos - Release of Security Interest in Specified IP (Syneos) [Executed] - Trademark#page2.tif

source=Syneos - Release of Security Interest in Specified IP (Syneos) [Executed] - Trademark#page3.tif

source=Syneos - Release of Security Interest in Specified IP (Syneos) [Executed] - Trademark#page4.tif

source=Syneos - Release of Security Interest in Specified IP (Syneos) [Executed] - Trademark#page5.tif

source=Syneos - Release of Security Interest in Specified IP (Syneos) [Executed] - Trademark#page6.tif

## RELEASE OF SECURITY INTEREST IN SPECIFIED INTELLECTUAL PROPERTY

This RELEASE OF SECURITY INTEREST IN SPECIFIED INTELLECTUAL PROPERTY (this “Release”), is dated as of November 17, 2020, and is made by JPMORGAN CHASE BANK, N.A., as administrative agent and collateral agent (in such capacities, the “Collateral Agent”) for the ratable benefit of the Secured Parties, in favor of SYNEOS HEALTH US, INC. a Delaware corporation (the “Grantor”). Capitalized terms used but not otherwise defined herein have the meanings given to such terms (whether directly or by reference to another agreement or document) in the Security Agreement (as defined below).

WHEREAS, the Grantor and the Collateral Agent are party to that certain Pledge and Security Agreement, dated as of August 1, 2017 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time and in effect on the date hereof, the “Security Agreement”);

WHEREAS, pursuant to the Security Agreement, the Grantor executed and delivered to the Collateral Agent that certain Intellectual Property Security Agreement dated as of August 1, 2017 (the “IP Security Agreement”);

WHEREAS, pursuant to the Security Agreement and the IP Security Agreement, the Grantor pledged, collaterally assigned, mortgaged, transferred and granted to the Collateral Agent its successors and permitted assigns, on behalf of and for the ratable benefit of the Secured Parties a continuing security interest in, among other collateral, all of the Grantor’s right, title and interest in, to and under all of the following, whether then owned or at any time thereafter acquired by or arising in favor of the Grantor and regardless of where located (the “Released IP Collateral”):

(A) the Trademark registrations and registration applications in the United States Patent and Trademark Office listed on Schedule A hereto but excluding any intent-to-use Trademark application prior to the filing and acceptance of a “Statement of Use”, “Declaration of Use”, “Amendment to Allege Use” or similar notice and/or filing with respect thereto, only to the extent, if any, that, and solely during the period if any, in which, the grant of such security interest may impair the validity or enforceability, or result in the voiding, of such intent-to-use Trademark application or any registration issuing therefrom under applicable Requirements of Law;

(B) the Patent registrations and pending applications in the United States Patent and Trademark Office listed on Schedule A hereto; and

(C) all proceeds of the foregoing,

in each case to the extent the foregoing items constitute Collateral;

WHEREAS, the IP Security Agreement was recorded at the United States Patent and Trademark Office on September 1, 2017 at Reel 6145, Frame 0562;

WHEREAS, the foregoing security interest in the Released IP Collateral was assigned to Collateral Agent (as successor to the original collateral agent under the Security Agreement) pursuant to the Successor Agent Agreement, dated as of March 26, 2019 and the Assignment of Security Interest in Intellectual Property, effective as of March 26, 2019 (the “Assignment”), which Assignment was recorded at the United States Patent and Trademark Office on March 26, 2019 at Reel 6601, Frame 0048;

WHEREAS, the Grantor has (a) informed the Collateral Agent that it intends to (i) transfer the Released IP Collateral to Adheris, LLC and (ii) immediately thereafter sell Adheris, LLC, and (b) certified that such transfer and sale and the transactions contemplated thereby are permitted by the Credit Agreement and the other Loan Documents; and

WHEREAS, pursuant to Section 7.12 of the Security Agreement, the Grantor has requested that the Collateral Agent execute and deliver this Release for recordation with the United States Patent and Trademark Office.

NOW, THEREFORE, in consideration of the foregoing and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Collateral Agent (on behalf of itself and the other Secured Parties) hereby terminates, releases and discharges its security interest in the Released IP Collateral, and hereby re-assigns, re-transfers and re-conveys to the Grantor any and all right, title and interest the Collateral Agent or any Secured Party may have in, to or under the Released IP Collateral.

This Release is applicable solely with respect to the Released IP Collateral and to no other Collateral arising under the Security Agreement or the IP Security Agreement (collectively, the "Retained Collateral"). The Collateral Agent's security interest, liens, rights and interests in the Retained Collateral shall not be, and shall not be deemed to be, released, terminated, discharged, impaired, interrupted or otherwise modified in any respect by this Release.

[Signature page follows]

IN WITNESS WHEREOF, the Collateral Agent has caused this Release to be executed by its duly authorized representative as of the date first above written.

JPMORGAN CHASE BANK, N.A.,  
as Collateral Agent

By:   
Name: Ling Li  
Title: Executive Director

**SCHEDULE A****RELEASED IP COLLATERAL****Trademarks**

<b>OWNER</b>	<b>REG. NO.</b>	<b>TRADEMARK</b>
Syneos Health US, Inc.	Registration No. 5,147,092	PATIENT inHOME
Syneos Health US, Inc.	Registration No. 5,147,089	PATIENT inOFFICE
Syneos Health US, Inc.	Registration No. 5,147,091	PATIENT inPHARMACY
Syneos Health US, Inc.	Registration No. 5,147,088	PHARMACIST inSTORE
Syneos Health US, Inc.	Registration No. 5,147,090	PRESCRIBER inOFFICE

**Patents**

<b>OWNER</b>	<b>PATENT NO.</b>	<b>TITLE</b>
Syneos Health US, Inc.	8,180,653	Pharmacy Network Computer System and Printer
Syneos Health US, Inc.	8,762,176	Pharmacy Network Computer System and Printer
Syneos Health US, Inc.	8,072,635	Pharmacy Printer System and Method
Syneos Health US, Inc.	8,531,714	Pharmacy Printer System and Method
Syneos Health US, Inc.	9,405,493	Pharmacy Printer System and Method
Syneos Health US, Inc.	9,524,375	Pharmacy Printer System and Method
Syneos Health US, Inc.	9,727,700	Pharmacy Printer System and Method
Syneos Health US, Inc.	7,987,125	System and method for special accounts
Syneos Health US, Inc.	7,778,930	System of performing a retrospective drug profile review of de-identified patients

Syneos Health US, Inc.	7,913,900	System of performing a retrospective drug profile review of de-identified patients
Syneos Health US, Inc.	7,309,001	System to Provide Specific Messages to Patients